[
  {
    "ts": null,
    "headline": "Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?",
    "summary": "NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.",
    "url": "https://finnhub.io/api/news?id=9e9305f46a38c875a486b06a2bf06ada91627c2540ef5f64ee347b0bc81c9171",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751637180,
      "headline": "Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?",
      "id": 135754022,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.",
      "url": "https://finnhub.io/api/news?id=9e9305f46a38c875a486b06a2bf06ada91627c2540ef5f64ee347b0bc81c9171"
    }
  },
  {
    "ts": null,
    "headline": "Take The Labor Market Data With A Pinch Of Salt",
    "summary": "June's labor market exceeded expectations, but Fed projections and trade tariffs loom. Check out why I think healthcare stocks could make some of the best buys.",
    "url": "https://finnhub.io/api/news?id=0ba0220706820927801ba8de207794066b1eba5cfda4d893c26d7895f4de518b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751618700,
      "headline": "Take The Labor Market Data With A Pinch Of Salt",
      "id": 135752290,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2165655874/image_2165655874.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "June's labor market exceeded expectations, but Fed projections and trade tariffs loom. Check out why I think healthcare stocks could make some of the best buys.",
      "url": "https://finnhub.io/api/news?id=0ba0220706820927801ba8de207794066b1eba5cfda4d893c26d7895f4de518b"
    }
  },
  {
    "ts": null,
    "headline": "UBS Sees Strong Sales Outlook for Eli Lilly’s Zepbound and Mounjaro",
    "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating and $1,050 price target on Eli Lilly & Company (NYSE:LLY), pointing to the pharmaceutical company’s dominant position in the market for treating obesity. Sales estimates for Eli Lilly & Company (NYSE:LLY)’s weight-loss treatment Zepbound […]",
    "url": "https://finnhub.io/api/news?id=79f65ea6443e3ed9e9bc7a0a4ab382e47644ada617d7f2366c48fa13b9b1c997",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751613756,
      "headline": "UBS Sees Strong Sales Outlook for Eli Lilly’s Zepbound and Mounjaro",
      "id": 135755389,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating and $1,050 price target on Eli Lilly & Company (NYSE:LLY), pointing to the pharmaceutical company’s dominant position in the market for treating obesity. Sales estimates for Eli Lilly & Company (NYSE:LLY)’s weight-loss treatment Zepbound […]",
      "url": "https://finnhub.io/api/news?id=79f65ea6443e3ed9e9bc7a0a4ab382e47644ada617d7f2366c48fa13b9b1c997"
    }
  },
  {
    "ts": null,
    "headline": "Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns.",
    "summary": "Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with Lilly and Novo.",
    "url": "https://finnhub.io/api/news?id=171fec0d3edd4b2fcaa0b6160aaefe6f9cfb77b19a0333cbcc11bbab38a3adff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751605260,
      "headline": "Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns.",
      "id": 135746969,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with Lilly and Novo.",
      "url": "https://finnhub.io/api/news?id=171fec0d3edd4b2fcaa0b6160aaefe6f9cfb77b19a0333cbcc11bbab38a3adff"
    }
  }
]